Navigation Links
ULURU Inc. Reports Third Quarter 2007 Results
Date:11/13/2007

with the Securities and Exchange Commission.

Contact: Company

Kerry P. Gray

President & CEO

Terry K. Wallberg

Vice President & CFO

(214) 905-5145

ULURU Inc.

SUMMARY OF RESULTS

(In thousands, except loss per share)

STATEMENT OF OPERATIONS DATA

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

REVENUES

License fees $14 $- 0 - $169 $155

Royalty income 83 101 220 353

Product sales - 0 - - 0 - - 0 - 76

Other 33 12 243 108

Total Revenues 130 113 632 692

COSTS AND EXPENSES

Cost of goods sold - 0 - - 0 - - 0 - 97

Research and development 455 389 1,574 1,343

General and administrative 821 351 2,110 1,096

Amortization 272 265 806 785

Depreciation 19 16 53 48

Total Costs and Expenses 1,567 1,021 4,543 3,369

OPERATING (LOSS) (1,437) (908) (3,911) (2,677)

Other Income (Expense)

Interest and

miscellaneous income 197 3 617 15

Interest expense - 0 - (617) (2) (1,601)

Commitment fee -

Standby Equity

Agreement - 0 - - 0 - - 0 - (1,788)

Liquidated damages
'/>"/>

SOURCE ULURU Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. ULURU Inc. to Present at UBS Global Life Sciences Conference 2007
2. ULURU Inc. Announces Odd-Lot Buy Back Offer
3. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Third Quarter Ended September 30, 2007 and Provide a Business Update
4. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
5. Haemacure Reports Third Quarter 2007 Results
6. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
7. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
8. MDS Reports Third Quarter 2007 Results
9. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
10. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
11. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)... Robert J. Reilly, Joins Aethon Team, PITTSBURGH,...aethon.com ), the leading developer of mobile robo...nounced that Robert J. Reilly has,joined the compa...icer., Reilly, who was most recently Vice Preside...pecialty Pharmacy Division, brings more than 30,ye...
(Date:7/25/2008)...ce to be presented at Fenway Park ... /PRNewswire/ -- CVS/pharmacy announced today,that...llion in just 21 days,through its annual in-store ... seventh year of the annual fundraising effort whi...ALS research. This year,s fundraiser took,place in...
(Date:7/25/2008)...ng to drop pounds, study finds , , FRIDA...ded Monday morning weigh-ins knows this unalterabl...Now, researchers have some science to back up diet...: Most people do eat more on the weekend, even whe...ulgences can wreak havoc on weight control, either...
(Date:7/25/2008)...re an Olympian, Professional Athlete, Elite Amateu...ed to Know about Hydration to Boost Sports Perform... Marina del Rey, Calif. (V...are heading to Beijing following years of intense ...of capturing an Olympic medal and securing their p...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:CVS/pharmacy Raises Record-breaking $4.4 Million for ALS Research Through Annual ALS Fundraising Campaign 2Health News:Weekends Tough on the Diet 2Health News:Weekends Tough on the Diet 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 2Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 3Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 4Health News:Hydration Will Be Key For Beijing Bound Olympians, What Every Athlete Must Know 5
...tching some rays has been shown to boost vitamin D... the risk of disease. Higher sun exposure during c...a reduced risk of multiple sclerosis, according to...ucted a study in Tasmania, which is located at hig...
...w research shows women who allow only short interv...d risk for developing complications. Researchers i...en birth twice between 1992 and 1998. Results of t...t births are much more likely to become pregnant a...
Indians Stay Away from Coke, Pepsi After Toxin Scare
...ctors usually prescribe antibiotics for problems l...e drugs, especially penicillin, may also protect a...ia prevent a problem that involves the blockage of...s often occur when cholesterol plaques in blood ve...
Other Medicine News:
(Date:7/24/2008)...Support Prognostic Value of Circulating Tumor Cell...rnational, prospective,clinical trial found the nu... indicator of progression-free and overall surviva...ording to a report published in the July 1,issue o...onducted in the US, the Netherlands, and the Unite...
(Date:7/24/2008)...AIN VIEW, Calif., July 24 /...nounced today that it has initiated,its second Pha...ine).,AZ-004 is an inhalation product candidate be... in patients with schizophrenia or bipolar disorde...and rapid pharmacokinetic,(PK) properties resultin...
(Date:7/24/2008)...New JIT Enrollment Program Speeds Oncology Patient...ech, Inc., a Research Management,Organization (RMO...,companies to provide research and site management...-in-Time (JIT) enrollment strategy. The new,trials...ular Non-Hodgkin,s,Lymphoma, Metastatic Breast Can...
(Date:7/24/2008)...A ANTIPOLIS, France, July 24 /PRNewswire-FirstCall...ced the top-line results from the 52-week,open lab...he completion of,the 301 phase 3 study for naproxc...ndings and efficacy was maintained for the one-yea...ts, global assessment scale. In,addition, the resu...
Breaking Medicine Technology:Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 2Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 2NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 3NicOx Announces Top-Line Results From Naproxcinod 52-Week 301 Safety Extension 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 1Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 2Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 3Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 4Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin 28R 29 4480 5Citrate appears to control buckyball clumping but environmental concerns remain 4478 1Citrate appears to control buckyball clumping but environmental concerns remain 4478 2Citrate appears to control buckyball clumping but environmental concerns remain 4478 3Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 1Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 2Shareholder Class Action Filed Against Humana Inc by The Law Firm of Schiffrin Barroway Topaz 26 Kessler LLP 16319 3Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 1Healthcare Workers Sue SEIU for Infringing on Free Speech Rights 16316 2
...NGTON--(BUSINESS WIRE)--May 22, 2007 - Alequel(TM)...tion, may be an,effective treatment for moderate-t...going double-blind, placebo controlled Phase II,st...nduced good,clinical remissions and improved patie...researchers from Hebrew University-Hadassah,Medica...
... results report no new stent thrombosis after two ...s., and BARCELONA, Spain, May 22, 2007,/PRNewswire...,announced four-year follow-up data from its TAXUS... safety and efficacy benefits,associated with a mo...(TM) paclitaxel-eluting stent system -- which is n...
Other Medicine Technology:Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 2Enzo Biochem Individualized Oral Immune Regulation Therapy May Be,Effective Approach to Treating Crohn's Disease 3Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 2Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes,for Moderate-Release Paclitaxel-Eluting Stent at Four Years 3
Desmarrres Lid Retractor, round serrated handle, polished finish, overall length 130 mm.
The Storz Protege is an anterior segment unit only.
The CV-12000 provides the surgeon with all the options to perform today's newest techniques.
Phaco-emulsification systems CV series
Medicine Products: